AUTHORS
Norman Park Peng Quek, MBChB, Diego Villa, MD2, Alina S. Gerrie, MD, FRCPC, MPH3, Christopher P. Venner, MD4, Andrew J. Cowan, MD5, Pedro Farinha, MD, PhD6, Andrew Lytle, MD, PhD7, Graham Slack, MD8, David Scott, MD9, Kerry Savage, MD, MSc, BSc10, Laurie H. Sehn, MD11
AFFILIATIONS
1 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
2 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
3 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
4 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
5 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
6 BC Cancer, Vancouver, British Columbia, Canada
7 BC Cancer, Vancouver, British Columbia, Canada
8 BC Cancer, Vancouver, British Columbia, Canada
9 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
10 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
11 BC Cancer and the University of British Columbia, Vancouver, British Columbia, Canada, BC Cancer, Vancouver, British Columbia, Canada
ABSTRACT
Background: Due to selection bias, clinical trial data are poorly reflective of real-world outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL). Pts deemed unsuitable for curative-intent chemoimmunotherapy are known to have inferior outcomes, but the proportion of pts represented, and survival expectations, are not well documented in the rituximab era. While promising novel therapies have been approved in the relapsed/refractory setting, these remain largely inaccessible in the frontline setting. We reviewed the frontline treatment landscape and associated outcomes for an unselected population of pts with newly diagnosed DLBCL in British Columbia (BC).
Method: Using the BC Cancer Centre for Lymphoid Cancer Database, we identified all pts with newly diagnosed DLBCL ≥18 years (y) of age in BC, between Mar 2001 (following availability of rituximab) and Apr 2026. Pts with PTLD, PMBCL, primary CNS lymphoma, transformed lymphoma, and composite/discordant lymphoma were excluded. Pts were stratified into three groups by treatment at diagnosis: curative-intent chemotherapy (cure-intent), palliative-intent chemotherapy (pall-chemo), or no chemotherapy (no-chemo). Cure-intent was defined as consisting of at least one cycle of an anthracycline or etoposide-substituted combination regimen, with dose reduction permitted.
Results: 5954 pts with newly diagnosed DLBCL were identified. The median age at presentation was 70 y (range 18 – 101), with a slight male preponderance (58%). The majority of pts were treated with cure-intent, 5028 (84%), relatively few received pall-chemo, 156 (3%), and 770 (13%) received no-chemo. Pts in the cure-intent group were significantly younger (median 68 y, range 18-96), compared with pall-chemo pts (median 82 y, range 46-96), and no-chemo pts (median 82 y, range 24-101), p <0.001. With median follow-up of 7.7 y, (range 0-24.6); 2-y, and 5-y overall survival (OS) for the entire cohort was 66.2% and 55.7% respectively; median OS was 6.9 y. Two-year and 5-y DSS for the entire cohort was 67.7% and 62.2% respectively. Most cure-intent pts (92%) received R-CHOP, 5% received etoposide-substituted R-CEOP, and 2% received other intensive regimens. Most cure-intent pts (92%) received at least 3 cycles of therapy. Outcomes in cure-intent pts were favorable, in keeping with expectations for a real-world cohort: 2-y and 5-y PFS, 68.8% and 57.1%; 2-y and 5-y OS, 75.7% and 64.4%; 2-y and 5-y DSS, 77.0%, 71.2%. Most pall-chemo pts received single-agent chemotherapy (69%); 19% received radiation therapy (RT). Outcomes in pall-chemo pts were extremely poor and largely comparable to that observed in the no-chemo cohort: 2-y and 5-y OS, 16.2% and 8.8%, median OS 3.7 months (m); 2-y and 5-y DSS, 18.7% and 14.5%. Outcomes in no-chemo pts were also extremely poor: 2-y and 5-y OS, 13.4% and 8.4%, median OS 1.7 m; 2-y and 5-y DSS, 15.4% and 11.9%. Most no-chemo pts were deemed too frail for treatment and received best supportive care, although 26% received RT. Examining treatment choice according to age, the percentage of pts treated with cure-intent diminished with age: 18-69y, 96%; 70-79y, 86%; >80y, 59%. In contrast, the percentage of pts receiving no-chemo increased with age: 18-69y, 3.7%; 70-79y, 12.1%; >80y, 33.9%.
Conclusions: While DLBCL is a highly curable entity, a substantial proportion (16% of all newly diagnosed pts, and approximately 40% of pts >80 years of age) in our real-world cohort were not treated with curative intent. These pts have a dismal outcome, with median OS of <4 m, regardless of the use of palliative chemotherapy. The low number of pts receiving palliative chemotherapy likely reflects standard clinical practice, whereby pts deemed appropriate for any chemotherapy are given a trial of curative-intent therapy, often with initial dose reduction. Pts with DLBCL who are unsuitable for curative-intent multi-agent chemoimmunotherapy represent a substantial group of pts who are not currently captured within most clinical trials and represent a significant unmet need. Ongoing efforts to evaluate novel chemotherapy-free options in the frontline setting are highly warranted, but treatment tolerance for this largely frail population will be an important consideration. These outcome data provide a benchmark for future novel therapy trials.
DISCLOSURES
Laurie H. Sehn, MD: AstraZeneca - Honoraria; BMS - Honoraria; BeOne/Beigene - Honoraria; Eli Lilly - Honoraria; Abbvie - Honoraria; Incyte - Honoraria; Kite/Gilead - Honoraria; Janssen - Honoraria; Roche/Genentech - Honoraria; Merck - Honoraria; Genmab - Honoraria; Chugai - Honoraria; Seagen - Honoraria; Roche/Genentech - Research Funding; BeOne/Beigene - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Roche/Genentech - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony)